Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US9266930B1 · kind B1 · utility
3Cited by
12References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 1999 |
| Grant date | Feb 23, 2016 |
| Priority date | — |
| Expiry date | Mar 30, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.